High throughput drug screening for neurodegenerative diseases
CompanyNeuron-D GmbH, Dresden, Germany
The Dresden-based start-up “Neuron-D GmbH” is developing a high-throughput system for testing drug candidates to treat neurodegenerative diseases. The technology is based on a 3D cell culture method, which replicates key features of neurons in the human brain and the pathology associated with neurodegeneration much better than conventional methods. The patented 3D brain model is customizable, cost-effective and delivers fast results. The approach is based on stem cells derived from healthy adults or patients and is aimed in particular at screening drugs against neurodegenerative diseases such as Alzheimer’s disease. The screening platform will be available in 2022.
Caghan Kizil
Added on: 05-11-2021
[1] https://www.bionity.com/en/news/1170370/dznes-first-spin-off-neurond-uses-innovative-technology-for-drug-testing.html[2] https://neurond.de/our-business-model
